Start pharmacoeconomic evaluation early in drug development Tracey Langsdale Newsletter Article 16 February 2013 Pages: 3 - 3
Healthcare rationing decisions should not be ‘dumped’ on doctors Newsletter Article 16 February 2013 Pages: 4 - 4
‘Reactive responses’ to drug wastage are not the answer Newsletter Article 16 February 2013 Pages: 6 - 6
Invasive vs conservative strategies for cardiovascular disease Newsletter Article 16 February 2013 Pages: 6 - 7
Influenza immunisation programme cost effective for elderly Newsletter Article 16 February 2013 Pages: 7 - 7
Learning from ‘ground-breaking work’ on rational drug use Carlene Todd Newsletter Article 16 February 2013 Pages: 8 - 9
Enoxaparin or warfarin in the prophylaxis of deep vein thrombosis? Newsletter Article 16 February 2013 Pages: 9 - 9
Increasing cost effectiveness in care for depression Newsletter Article 16 February 2013 Pages: 10 - 10
Comparing antibacterial regimens in acute cystitis Newsletter Article 16 February 2013 Pages: 10 - 10
Empirical fluconazole strategy of choice in oesophageal candidiasis Newsletter Article 16 February 2013 Pages: 11 - 11
CMV immune globulin titre-guided regimen cost effective Newsletter Article 16 February 2013 Pages: 11 - 11
Look at a disease-specific measure to assess QOL in CAD Newsletter Article 16 February 2013 Pages: 12 - 12
QOL associated with nizatidine maintenance vs intermittent therapy Newsletter Article 16 February 2013 Pages: 12 - 12
QOL impact of recombinant G-CSF in congenital agranulocytosis Newsletter Article 16 February 2013 Pages: 13 - 13
Future changes in the worldwide price, volume and value of drugs Newsletter Article 16 February 2013 Pages: 15 - 15
Practice guidelines and drug reimbursement in France Newsletter Article 16 February 2013 Pages: 16 - 16